Anti-obesity pharmacotherapy
obesity drugs · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Pharmacological treatment of obesity as an adjunct to lifestyle, now dominated by incretin-based agents producing substantial weight loss and cardiometabolic benefit. Patient selection, titration and monitoring are key.
Red flags
- Severe persistent vomiting or features of gastroparesis
- Acute pancreatitis or gallbladder disease
- Personal/family history of medullary thyroid cancer or MEN2 (GLP-1 contraindication)
- Suicidal ideation (naltrexone/bupropion)
- Rapid excessive weight loss or malnutrition
Assessment
Differential diagnosis
- Hypothyroidism
- Cushing syndrome
- Hypothalamic/genetic obesity
- Drug-induced weight gain
- Oedematous states
Investigations
- BMI and waist circumference
- HbA1c, lipids, blood pressure and liver function
- TSH to exclude hypothyroidism
- Screen for obesity-related complications (sleep apnoea, MASLD)
- Assessment of eating pattern and comorbidity
Management
- Confirm obesity (BMI >=30, or >=27 with comorbidity) and exclude secondary causes
- Establish structured lifestyle intervention as the foundation
- Discuss realistic expectations, side effects and duration of therapy
- Select agent by efficacy, comorbidity and availability
- Start incretin therapy at low dose and titrate slowly to limit gastrointestinal effects
- Monitor weight, metabolic parameters and tolerability
- Review response: consider stopping/switching if <5% loss after adequate trial
- Address gallstone, pancreatitis and (for some agents) psychiatric risks
- Plan for weight regain on discontinuation and counsel on long-term therapy
- Refer suitable high-BMI patients for bariatric surgery assessment
Drugs & doses
Semaglutide 0.25 mg SC weekly titrated to 2.4 mg (Wegovy)
Tirzepatide 2.5 mg SC weekly titrated to 15 mg
Liraglutide 0.6 mg SC daily titrated to 3 mg
Orlistat 120 mg PO three times daily with meals
Naltrexone/bupropion combination as an alternative
Disposition
Prescribe within weight-management pathways; refer to specialist/bariatric services for high BMI, complex comorbidity or inadequate response.
Complications & pitfalls
- Gastrointestinal intolerance
- Gallstones and pancreatitis
- Muscle mass loss with rapid weight loss
- Weight regain after stopping
- Nutrient deficiencies
Exam pearls
- Incretin agents require slow titration to minimise nausea and improve adherence
- Weight tends to return after stopping, so frame treatment as long-term
- Avoid GLP-1/GIP agents with a personal or family history of medullary thyroid carcinoma or MEN2
- Combine pharmacotherapy with sustained lifestyle change and consider surgery at higher BMI
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.